The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Molecular targeted therapy for osteosarcoma using glycogen synthase kinase-3 beta (GSK-3β) inhibitors.
Shingo Shimozaki
No relevant relationships to disclose
Norio Yamamoto
No relevant relationships to disclose
Hideji Nishida
No relevant relationships to disclose
Hiroaki Kimura
No relevant relationships to disclose
Akihiko Takeuchi
No relevant relationships to disclose
Takashi Kato
No relevant relationships to disclose
Yu Aoki
No relevant relationships to disclose
Takashi Higuchi
No relevant relationships to disclose
Toshinari Minamoto
No relevant relationships to disclose
Hiroyuki Tsuchiya
No relevant relationships to disclose